The Specialists - Areas of Specialisation - Pain therapy

Dr. med. Holger Kaube
Facharzt für  Neurologie

Neurologie und Kopfschmerzzentrum
Münchner  Freiheit
Leopoldstr. 59
80802 München

Tel.         +49 (0) 89 /38 99 77 – 0
Fax         +49 (0) 89 /38 99 77 – 22

Mail: info@neuro-one.de

Curriculum Vitae

Studiengang:

Beruflicher Werdegang:

Erfahrungen als Klinischer Prüfarzt

Teilnahme als Prüfarzt an mehr als 15 Studien in Phasen 1, 2 und 3 mit kommerziellen pharmazeutischen Sponsor und 7 „Investigator initiated“ Studien

Indikationen Migräne Akutbehandlung, menstruelle Migräneprophylaxe, Migräneaura-Behandlung, Migräneprophylaxe, Spannungskopfschmerzprophylaxe, Clusterkopfschmerz-Kurzprävention, Schmerzmittelentzugstherapie, Guillain-Barre-Syndrom, akute Lumbago, Schlafstörungen

Mitgliedschaften und weitere Positionen

• Mitglied des Landesbeirat Schmerzversorgung des Sozialministeriums Baden-Württemberg
• Ehrenmitglied der British Neuropsychiatry Association
• International Headache Society (IHS)
• International Society for the Study of Pain (IASP)
• Deutsche Migräne- und Kopfschmerzgesellschaft (DMKG)
• Deutsche Gesellschaft zum Studium des Schmerzes (DGSS)
• Berufsverband der Schmerztherapeuten Deutschland (BVSD)

Advisory Board, Berater  und Fortbildungen

• Merck, Sharp & Dohme (Deutschland), Boston Scientific (Europe), Medtronic (Europe), St. Jude Medical (Europe), Pfizer Pharma (Deutschland), Berlin Chemie, Boehringer Ingelheim Pharma (Deutschland)
• Ehrenmitglied und wissenschaftlicher Beirat der Clusterkopfschmerz- Selbsthilfegruppen e.V.

Veröffentlichungen
(77 Publikationen, 2 Publikationen in Nature Medicine und Science)

1. Mueller D, Obermann M, et al. Electrically evoked nociceptive potentials for early detection of diabetic small-fiber neuropathy. Eur J Neurol. 2010 [Epub ahead of print]
2. Weiller C, Kaube H. Posterior hypoperfusion in migraine without aura? Cephalalgia. 2009. [Epub ahead of print]
3. Obermann M, Pleger B, de Greiff A, Stude P, Kaube H, Diener HC, Katsarava Z. Temporal summation of trigeminal pain in human anterior cingulate cortex. Neuroimage. 2009 ;46(1):p193-200.
4. Wolter, T., Kaube, H., Mohadjer M. High cervical epidural neurostimulation for cluster headache: case report and review of the literature. Cephalalgia, 2008 28(10): 1091-4
5. Artemenko, A.R., et al., Effects of topiramate on migraine frequency and cortical excitability in patients with frequent migraine. Cephalalgia, 2008. 28(3): 203-8.
6. Obermann, M., et al., Impaired trigeminal nociceptive processing in patients with trigeminal neuralgia. Neurology, 2007. 69(9): 835-41.
7. Obermann, M., et al., Correlation of epidermal nerve fiber density with pain-related evoked potentials in HIV neuropathy. Pain, 2007.
8. Magis, D., et al., Evaluation and proposal for optimization of neurophysiological tests in migraine: part 2--neuroimaging and the nitroglycerin test. Cephalalgia, 2007. 27(12): 1339-59.
9. Magis, D., et al., Evaluation and proposal for optimalization of neurophysiological tests in migraine: part 1--electrophysiological tests. Cephalalgia, 2007. 27(12): 1323-38.
10. Dzagnidze, A., et al., Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci, 2007. 27(35): 9451-7.
11. Busch, V., et al., Sumatriptan and corneal reflexes in headache-free migraine patients: a randomized and placebo-controlled crossover study. Cephalalgia, 2007. 27(2): 165-72.
12. Busch, V., et al., Occipital nerve blockade in chronic cluster headache patients and functional connectivity between trigeminal and occipital nerves. Cephalalgia, 2007. 27(11): 1206-14.
13. Sandor, P.S., et al., Prosopagnosia as symptom of migraine with aura: a case report. Cephalalgia, 2006. 26(3): 345-8.
14. Sandor, P.S., et al., Onset of cluster headache triggered by emotional effect: a case report. J Neurol Neurosurg Psychiatry, 2006. 77(9): 1097-9.
15. Rejdak, K., et al., Increased urinary excretion of nitric oxide metabolites in longitudinally monitored migraine patients. Eur J Neurol, 2006. 13(12): 1346-51.
16. Paemeleire, K., et al., Practical management of medication-overuse headache. Acta Neurol Belg, 2006. 106(2): 43-51.
17. Katsarava, Z., et al., Pain related potentials by electrical stimulation of skin for detection of small-fiber neuropathy in HIV. J Neurol, 2006. 253(12): 1581-4.
18. Katsarava, Z., et al., A novel method of eliciting pain-related potentials by transcutaneous electrical stimulation. Headache, 2006. 46(10): 1511-7.
19. Busch, V., et al., Functional connectivity between trigeminal and occipital nerves revealed by occipital nerve blockade and nociceptive blink reflexes. Cephalalgia, 2006. 26(1): 50-5.
20. Baad-Hansen, L., et al., Blink reflexes in patients with atypical odontalgia and matched healthy controls. Exp Brain Res, 2006. 172(4): 498-506.
21. Ayzenberg, I., et al., Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia, 2006. 26(9): 1106-14.
22. Afridi, S.K., et al., A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain, 2005. 128(Pt 4): 932-9.
23. Afridi, S.K., et al., A positron emission tomographic study in spontaneous migraine. Arch Neurol, 2005. 62(8): 1270-5.
24. Afridi, S., H. Kaube, and P.J. Goadsby, Occipital activation in glyceryl trinitrate induced migraine with visual aura. J Neurol Neurosurg Psychiatry, 2005. 76(8): 1158-60.
25. Singer, T., et al., Empathy for pain involves the affective but not sensory components of pain. Science, 2004. 303(5661): 1157-62.
26. Katsarava, Z., et al., Differences of anti-nociceptive mechanisms of migraine drugs on the trigeminal pain processing during and outside acute migraine attacks. Cephalalgia, 2004. 24(8): 657-62.
27. Gil-Gouveia, R., P.A. Wilkinson, and H. Kaube, Severe hemiplegic migraine attack precipitated by fentanyl sedation for esophagogastroscopy. Neurology, 2004. 63(12): 2446-7.
28. Giffin, N.J., et al., The effect of multiple stimuli on the modulation of the 'nociceptive' blink reflex. Pain, 2004. 108(1-2): 124-8.
29. Cohen, A.S. and H. Kaube, Rare nocturnal headaches. Curr Opin Neurol, 2004. 17(3): 295-9.
30. Akerman, S., H. Kaube, and P.J. Goadsby, Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther, 2004. 309(1): 56-63.
31. Akerman, S., H. Kaube, and P.J. Goadsby, Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol, 2004. 142(8): 1354-60.
32. Afridi, S.K., H. Kaube, and P.J. Goadsby, Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain, 2004. 110(3): 675-80.
33. Kowacs, F., et al., Nociceptive-specific blink reflex and glyceryl trinitrate infusion in healthy volunteers. Eur J Neurol, 2003. 10(3): 295-9.
34. Katsarava, Z., et al., Abnormal habituation of 'nociceptive' blink reflex in migraine--evidence for increased excitability of trigeminal nociception. Cephalalgia, 2003. 23(8): 814-9.
35. Katsarava, Z., et al., Symptomatic migraine and sensitization of trigeminal nociception associated with contralateral pontine cavernoma. Pain, 2003. 105(1-2): 381-4.
36. Giffin, N.J., et al., Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia, 2003. 23(4): 287-92.
37. Akerman, S., H. Kaube, and P.J. Goadsby, Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation. Br J Pharmacol, 2003. 140(4): 718-24.
38. Afridi, S. and H. Kaube, Prophylactic Therapy for Migraine. Curr Treat Options Neurol, 2003. 5(6): 431-440.
39. Knight, Y.E., et al., P/Q-type calcium-channel blockade in the periaqueductal gray facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci, 2002. 22(5): RC213.
40. Kaube, H., et al., Acute migraine headache: possible sensitization of neurons in the spinal trigeminal nucleus? Neurology, 2002. 58(8): 1234-8.
41. Katsarava, Z., et al., Sensitization of trigeminal nociception specific for migraine but not pain of sinusitis. Neurology, 2002. 59(9): 1450-3.
42. Katsarava, Z., et al., Selective damage of trigeminal Adelta fibres in Raeder's syndrome following dissection of the ICA detected by a nociceptive blink reflex. Cephalalgia, 2002. 22(2): 151-3.
43. Katsarava, Z., et al., Optimized stimulation and recording parameters of human 'nociception specific' blink reflex recordings. Clin Neurophysiol, 2002. 113(12): 1932-6.
44. Giffin, N.J. and H. Kaube, The electrophysiology of migraine. Curr Opin Neurol, 2002. 15(3): 303-9.
45. Akerman, S., et al., Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol, 2002. 137(1): 62-8.
46. Akerman, S., et al., The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. Eur J Pharmacol, 2002. 452(2): 223-8.
47. Akerman, S., et al., The role of histamine in dural vessel dilation. Brain Res, 2002. 956(1): 96-102.
48. Ellrich, J., et al., Is the R3 component of the human blink reflex nociceptive in origin? Pain, 2001. 91(3): 389-95.
49. Kaube, H., P. Mummel, and S. Koeppen, Ethambutol related headache in HIV infection: sensitisation to normal CSF pressure? A case report. J Neurol Neurosurg Psychiatry, 2000. 68(4): 535-6.
50. Kaube, H., et al., A new method to increase nociception specificity of the human blink reflex. Clin Neurophysiol, 2000. 111(3): 413-6.
51. Kaube, H., et al., Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology, 2000. 55(1): 139-41.
52. Diener, H.C., H. Kaube, and V. Limmroth, [Migraine: clinical aspects, diagnosis and pharmacotherapy]. Internist (Berl), 2000. 41(4): 390-8.
53. Kaube, H., et al., Vasodilator agents and supracollicular transection fail to inhibit cortical spreading depression in the cat. Cephalalgia, 1999. 19(6): 592-7.
54. Diener, H.C., H. Kaube, and V. Limmroth, Antimigraine drugs. J Neurol, 1999. 246(7): 515-9.
55. Diener, H.C., H. Kaube, and V. Limmroth, [Migraine. Symptoms, diagnosis and drug therapy]. Anaesthesist, 1999. 48(11): 845-56.
56. Scherbaum, N., et al., Alternative strategies of opiate detoxification: evaluation of the so-called ultra-rapid detoxification. Pharmacopsychiatry, 1998. 31(6): 205-9.
57. May, A., et al., Experimental cranial pain elicited by capsaicin: a PET study. Pain, 1998. 74(1): 61-6.
58. Diener, H.C., H. Kaube, and V. Limmroth, A practical guide to the management and prevention of migraine. Drugs, 1998. 56(5): 811-24.
59. Diener, H.C. and H. Kaube, [Migraine: epidemiology, clinical aspects and diagnosis]. Dtsch Med Wochenschr, 1998. 123(47): 1417-8.
60. Kaube, H. and H.C. Diener, [Differential diagnosis of acute migraine attacks]. Med Klin (Munich), 1997. 92(3): 145-6.
61. Diener, H.C., et al., Emerging treatments in headache. Eur Neurol, 1997. 38(3): 167-74.
62. Kaube, H. and V. Limmroth, [Animal models and their results in relation to the therapy of migraine]. Schmerz, 1996. 10(3): 114-20.
63. Hoskin, K.L., H. Kaube, and P.J. Goadsby, Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiological study. Brain, 1996. 119 ( Pt 1): 249-56.
64. Hoskin, K.L., H. Kaube, and P.J. Goadsby, Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain, 1996. 119 ( Pt 5): 1419-28.
65. Weiller, C., et al., Brain stem activation in spontaneous human migraine attacks. Nat Med, 1995. 1(7): 658-60.
66. Kaube, H., A. May, and V. Pfaffenrath, Sumatriptan. BMJ, 1994. 308(6943): 1573-4.
67. Kaube, H., K.L. Hoskin, and P.J. Goadsby, Lignocaine and headache: an electrophysiological study in the cat with supporting clinical observations in man. J Neurol, 1994. 241(7): 415-20.
68. Kaube, H. and P.J. Goadsby, Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat. Eur Neurol, 1994. 34(1): 30-5.
69. Kaube, H., et al., Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. Brain Res, 1993. 629(1): 95-102.
70. Kaube, H., K.L. Hoskin, and P.J. Goadsby, Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol, 1993. 109(3): 788-92.
71. Kaube, H., K.L. Hoskin, and P.J. Goadsby, Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache, 1993. 33(10): 541-4.
72. Kaube, H., K.L. Hoskin, and P.J. Goadsby, Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat. Cephalalgia, 1992. 12(3): 133-6.
73. Goadsby, P.J., H. Kaube, and K.L. Hoskin, Nitric oxide synthesis couples cerebral blood flow and metabolism. Brain Res, 1992. 595(1): 167-70.
74. Pfaffenrath, V., et al., Cerebrovascular risk factors in migraine with prolonged aura and without aura. Cephalalgia, 1991. 11(6): 257-61.
75. Pfaffenrath, V., et al., MMPI personality profiles in patients with primary headache syndromes. Cephalalgia, 1991. 11(6): 263-8.
76. Kaube, H. and E. Biemer, [Results of sex change operations in 30 transsexual patients: psychosocial and sexual adaptation--surgical complications]. Handchir Mikrochir Plast Chir, 1991. 23(5): 276-8.
77. Pfaffenrath, V. and H. Kaube, Diagnostics of cervicogenic headache. Funct Neurol, 1990. 5(2): 159-64.

• Kopfschmerzen
• Diagnostik, Akutbehandlung und Vorbeugung von Kopfschmerzen
• Medikamentöse und nicht medikamentöse Therapien
• Rolle von Hormonen, Magen- und Darmstörungen und Nahrungsmittelunverträglichkeiten bei Kopfschmerzen
• Beratung über operative Verfahren bei schwersten chronischen Kopfschmerzen (Cluster-KS und andere)